Fen-Phen Stats & Data

Fenfluramine’s active metabolite norfenfluramine is a potent 5‑HT2B receptor agonist; 5‑HT2B activation on cardiac valvular interstitial cells is strongly linked to valvular fibroplasia and regurgitation, the mechanistic basis for Fen‑Phen–associated valvular heart disease (VHD). Daily or prolonged courses markedly increase risk; there is no known completely safe exposure threshold. Modern fenfluramine use (for Dravet/LGS) mandates baseline and periodic echocardiograms due to risks of VHD and pulmonary arterial hypertension—illustrating that repeated exposure warrants cardiac surveillance. Phentermine contributes sympathomimetic effects (NE ≫ DA) and can precipitate hypertension, tachycardia, hyperthermia, anxiety, and insomnia; acute stimulant toxicity is managed with benzodiazepines first‑line, avoiding β‑blocker monotherapy. Fenfluramine is metabolized by multiple CYPs (1A2, 2B6, 2D6, 2C9, 2C19, 3A4); potent inhibitors (e.g., quinidine for CYP2D6, fluvoxamine for CYP1A2) can increase fenfluramine/norfenfluramine levels. Poor CYP2D6 metabolizers show reduced dexfenfluramine clearance in vitro; clinical exposures can vary. Combining with serotonergic agents (SSRIs/SNRIs/MAOIs/MDMA/DXM/tramadol/meperidine/linezolid) increases the risk of serotonin syndrome; onset can be rapid after dose or medication changes. Due to long half‑lives (~20 h each), avoid redosing within 24–48 h; accumulation increases cardiovascular and serotonergic risks. Avoid use in pregnancy, uncontrolled hypertension, coronary disease, valvular disease, pulmonary hypertension, glaucoma, or hyperthyroidism. Hydration, temperature awareness, and nutrition are essential: anorexia, exertion, and insomnia increase dehydration and hyperthermia risk. Drug checking cannot confirm fenfluramine with standard reagents; misrepresentation/substitution is plausible—exercise extra caution.